Thread by @Sarkarassetmgmt

#Gujaratthemis #Gujthemis Q4FY23 earnings call
1. Slowness in tendering witnessed last quarter continued during this quarter as well
2. Rifamycin-O, continued to see decent demand in the market
3. Rifa-S demand was low since this is largely a tender-driven segment.

4. Capex plan of Rs200cr for over 2+ years is progressing as per plan
5. New warehouse, R&D & API block will be ready by September 23, fermentation facility to be ready by Dec 24
6. Out of Rs200cr, Investing 80 cr in phase one of the fermentation block & rest into the API block.

7. In R&D block total spend is Rs42cr
8. Decided to put up 2 CGMP pilot facility
9. Rifaximin under patent till 2029. Expect europe to open up next year & US by 2028
10. Once these tenders open up, usually the supply contract is for two years. Global fund have started opening up

11. Running the plant for Rifa-S and Rifa-O at full capacity r
12. API block to start giving both top line & bottom line in the FY25
13. WHO recommendation to use Rifapentine will affect the company positively as same intermediates are used
14. Plan to manufacture Rifapentine